MediWound Ltd. (NASDAQ:MDWD) Receives $31.25 Consensus Price Target from Analysts

Shares of MediWound Ltd. (NASDAQ:MDWD - Get Free Report) have been assigned an average recommendation of "Buy" from the five brokerages that are covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $31.80.

A number of research analysts recently issued reports on the company. Wall Street Zen raised MediWound to a "sell" rating in a report on Friday, March 21st. HC Wainwright set a $31.00 price target on MediWound and gave the company a "buy" rating in a report on Thursday, May 22nd. Craig Hallum assumed coverage on MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 price target for the company. Oppenheimer assumed coverage on MediWound in a report on Monday. They issued an "outperform" rating and a $34.00 price target for the company. Finally, Alliance Global Partners assumed coverage on MediWound in a report on Friday, May 2nd. They issued a "buy" rating and a $25.00 price target for the company.

MediWound Stock Performance

Shares of NASDAQ:MDWD traded down $0.65 on Monday, hitting $21.59. The stock had a trading volume of 89,683 shares, compared to its average volume of 91,819. MediWound has a twelve month low of $12.78 and a twelve month high of $24.00. The firm's 50 day moving average price is $18.00 and its 200-day moving average price is $17.82. The company has a market capitalization of $233.34 million, a price-to-earnings ratio of -7.44 and a beta of 0.30.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.58. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The company had revenue of $3.96 million for the quarter, compared to the consensus estimate of $5.20 million. During the same quarter in the previous year, the company earned ($1.05) EPS. As a group, sell-side analysts predict that MediWound will post -2.66 EPS for the current year.

Institutional Trading of MediWound

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its holdings in MediWound by 4.4% during the 1st quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company's stock worth $176,000 after purchasing an additional 481 shares during the last quarter. Corebridge Financial Inc. increased its stake in shares of MediWound by 17.1% in the 1st quarter. Corebridge Financial Inc. now owns 4,559 shares of the biopharmaceutical company's stock valued at $71,000 after acquiring an additional 665 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock valued at $85,000 after acquiring an additional 999 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of MediWound by 154.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 1,162 shares during the last quarter. Finally, Barclays PLC increased its stake in shares of MediWound by 11.2% in the 4th quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company's stock valued at $221,000 after acquiring an additional 1,249 shares during the last quarter. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.